← All diseases
Infectious diseases
Drug-resistant tuberculosis
Do you want to receive a message when there is new research on Drug-resistant tuberculosis? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, above each publication appears one sentence explaining what was investigated — and you receive a notification as soon as new research on Drug-resistant tuberculosis becomes available. View what Premium costs.
Publications and studies (1454)
- Isolated Forearm Abscess with Bilateral Psoas Abscesses: An Unusual Presentation of Extrapulmonary Preextensively Drug-resistant Tuberculosis without Pulmonary Involvement. (2026/07/22) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Diagnostic Discordance During MDR-TB Treatment: Retrospective Identification of Mycobacterium avium Complex-Associated Nontuberculous Mycobacterium by Whole-Genome Sequencing. (2026/07/22) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Heteroresistance in Mycobacterium tuberculosis: from molecular mechanisms and advanced detection to clinical implications. (2026/07/22) ♡
- Whole-genome sequencing reveals lineage-associated drug resistance and enables machine learning-based prediction in Mycobacterium tuberculosis clinical isolates. (2026/07/22) ♡
- Tuberculosis notifications in Australia, 2019-2020. (2026/07/21) ♡
- Genomic insights into low-level rifampicin resistance mediated by borderline rpoB mutations in Mycobacterium tuberculosis: prevalence and phylogeny in Northeast China. (2026/07/21) ♡
- Towards culture-free sequencing of Mycobacterium tuberculosis: evaluating new targeted and whole-genome approaches for genotyping and drug resistance profiling. (2026/07/21) ♡
- The First Documented Case of Congenital Drug-Resistant Tuberculosis in Indonesia: A Case Report. (2026/07/20) ♡
- Characteristics, Treatment Strategies, and Long-term Health Outcomes of People With Bedaquiline-resistant Tuberculosis in Karakalpakstan, Uzbekistan-A Retrospective Cohort Study. (2026/07/20) ♡
- Drug resistance in tuberculous meningitis: A laboratory-based observational study from Northern India's tertiary care referral centre. (2026/07/20) ♡
- Multidrug resistant tuberculosis (MDR-TB) in Eritrea: a retrospective cohort analysis of mortality and associated factors (2013 - 2023). (2026/07/20) ♡
- MTK_MCPA: A novel magnesium-competitive inhibitor of Mycobacterium tuberculosis thymidylate kinase. (2026/07/17) ♡
- National and subnational burden of HIV-negative MDR-TB in China, 1990-2023: Spatio-temporal heterogeneity, long-term trends, and projections. (2026/07/17) ♡
- From linezolid to contezolid: a strategy for safe continuation of therapy in complex tuberculosis. (2026/07/17) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Associated characteristics of multidrug-resistant tuberculosis (MDR-TB) cases in Sub-Saharan Africa: a systematic review and meta-analysis. (2026/07/16) ♡
- Community-based, peer-led psychosocial support to address stigma and reduce depression among adults with tuberculosis in Indonesia: A prospective interventional cohort study. (2026/07/16) ♡
- Hepatic and splenic tuberculosis following infliximab therapy for refractory ulcerative colitis: a case report and literature review. (2026/07/16) ♡
- Performance of next-generation sequencing technologies for detecting drug-resistant tuberculosis in people with pulmonary tuberculosis. (2026/07/15) ♡
- Longer vs. shorter all-oral bedaquiline-based regimens for drug-resistant tuberculosis: real-world evidence from a high-burden setting. (2026/07/15) ♡
- Assessment of differentially culturable tubercle bacteria assays for the detection of tuberculosis infection in asymptomatic household contacts and the implications for intra-household transmission: a longitudinal cohort study. (2026/07/15) ♡
- "I Would Have to Hold Him and Pin Him Down": Caregiver Experiences of Administering Drug-Resistant Tuberculosis Treatment to Children in KwaZulu-Natal, South Africa. (2026/07/15) ♡
- Clinical and Microbiological Characteristics Associated with Treatment Outcomes Among Rifampicin-Resistant Tuberculosis Patients in Limpopo Province. (2026/07/14) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. High-dose linezolid during BPaL implementation for pre-extensively drug-resistant TB or failure/intolerance of rifampicin-resistant TB regimens. (2026/07/13) ♡
- Quantifying emergent drug-resistant TB using laboratory data and record-linkage methods. (2026/07/13) ♡
- Nurse case management to improve multidrug-resistant TB: a cluster-randomised trial. (2026/07/13) ♡
- Household costs and health-related quality of life of childhood multidrug-resistant TB in Western Cape, South Africa. (2026/07/13) ♡
- Genomic profile and infection dynamics of Kashi_RDG1 (KRDG1), a novel cluster K1 mycobacteriophage infecting mycobacterial hosts. (2026/07/13) ♡
- A Short-Course Regimen Containing Delamanid, Bedaquiline and Linezolid for the Treatment of Drug-Resistant Tuberculosis: A Retrospective Study from China. (2026/07/10) ♡
- Fluoroquinolone resistance and mutation profiles in Mycobacterium tuberculosis through whole genome sequencing in Fujian province, China. (2026/07/09) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Immunotherapy for tuberculosis: emerging modalities, cross-disciplinary innovations, and roadmaps for drug-resistant disease. (2026/07/09) ♡
- Population-level and longitudinal MIC distributions for antimicrobials against drug-resistant Mycobacterium tuberculosis in Wuxi, a low-epidemic city in China, from 2019 to 2023. (2026/07/08) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Current Landscape of Molecular Diagnostic Tests and Emerging Tools for Tuberculosis and Drug Resistance. (2026/07/07) ♡
- Evaluation of the GenoScreen Deeplex Myc-TB workflow for drug-resistant tuberculosis testing in South Africa. (2026/07/07) ♡
- Body Mass Index Trajectories Among Patients with Drug-Susceptible and Drug-Resistant Tuberculosis in Northwest Ethiopia. (2026/07/07) ♡
- Fucoidan-Functionalized Nanoparticles for Antimycobacterial Therapy: A Promising Approach against Drug-Resistant Mycobacterium tuberculosis Strains. (2026/07/03) ♡
- Divergent Trajectories of Pediatric All-Form Tuberculosis and Multidrug-Resistant Tuberculosis from 1990 to 2021. (2026/07/03) ♡
- Temporal dynamics and regional disparities in HIV/AIDS and extensively drug-resistant tuberculosis mortality in South Asia: A systemic analysis of global burden of disease data (1993-2021). (2026/07/01) ♡
- Utility of second sample testing in Indian children suffering from tuberculosis with rifampicin indeterminate results on Xpert MTB/Rif and Xpert Ultra assays. (2026/07/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Limited success and high attrition in the 9-month all-oral regimen for MDR-TB: Evidence from a tertiary care setting in Indonesia. (2026/07/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Imipenem-cilastatin and Linezolid induced black hairy tongue and teeth used in an Extremely drug resistant tuberculosis (XXDR)- case report and its clinical implications. (2026/07/01) ♡
- Alarming levels of fluoroquinolone resistance among MDR-TB patients in Poland: molecular and phenotypic analysis. (2026/07/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Immunotherapy for tuberculosis: current landscape, mechanistic insights, and translational perspectives. (2026/07/01) ♡
- A hospital-based genomic analysis reveals predominance of ST215 Mycobacterium tuberculosis with low drug resistance. (2026/07/01) ♡
- Clinical characteristics, drug resistance profiles, and inflammatory cytokine signatures in newly treated versus retreated MDR/RR-TB patients: associations with treatment outcomes. (2026/07/01) ♡
- Kinetical Analysis of Mutant PZase Enzyme To Uncover The Pyrazinamide Resistance In Mycobacterium tuberculosis Clinical Isolates. (2026/07/01) ♡
- Global, regional, and national burden of tuberculosis and multidrug-resistant tuberculosis by HIV status, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. (2026/07/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. In vitro pharmacokinetics and pharmacodynamics of the diarylquinoline TBAJ-587 and its metabolites against Mycobacterium tuberculosis. (2026/06/29) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Reimagining tuberculosis elimination in India: diagnostics, drug resistance, and digital health strategies. (2026/06/29) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Herbal supplements and anti-tuberculosis therapy: unlocking hidden interactions for better multidrug-resistant tuberculosis management. (2026/06/25) ♡
- Exploring the antimycobacterial profile of N-alkyl imidazoles. (2026/06/23) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.